211 related articles for article (PubMed ID: 35806224)
21. Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape.
Mastellos DC; Ricklin D; Yancopoulou D; Risitano A; Lambris JD
Expert Rev Hematol; 2014 Oct; 7(5):583-98. PubMed ID: 25213458
[TBL] [Abstract][Full Text] [Related]
22. Current and future pharmacologic complement inhibitors.
Risitano AM
Hematol Oncol Clin North Am; 2015 Jun; 29(3):561-82. PubMed ID: 26043392
[TBL] [Abstract][Full Text] [Related]
23. Safety of current treatments for paroxysmal nocturnal hemoglobinuria.
Lee SE; Lee JW
Expert Opin Drug Saf; 2021 Feb; 20(2):171-179. PubMed ID: 33249943
[No Abstract] [Full Text] [Related]
24. Drugs that inhibit complement.
Schrezenmeier H; Höchsmann B
Transfus Apher Sci; 2012 Feb; 46(1):87-92. PubMed ID: 22169380
[TBL] [Abstract][Full Text] [Related]
25. Cost burden of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria receiving ravulizumab versus eculizumab.
Tomazos I; Sierra JR; Johnston KM; Cheung A; Brodsky RA; Weitz IC
Hematology; 2020 Dec; 25(1):327-334. PubMed ID: 32856539
[No Abstract] [Full Text] [Related]
26. Frequency and perturbations of various peripheral blood cell populations before and after eculizumab treatment in paroxysmal nocturnal hemoglobinuria.
Gurnari C; Graham AC; Efanov A; Pagliuca S; Durrani J; Awada H; Patel BJ; Lichtin AE; Visconte V; Sekeres MA; Maciejewski JP
Blood Cells Mol Dis; 2021 Mar; 87():102528. PubMed ID: 33341510
[TBL] [Abstract][Full Text] [Related]
27. Different Levels of Incomplete Terminal Pathway Inhibition by Eculizumab and the Clinical Response of PNH Patients.
Harder MJ; Höchsmann B; Dopler A; Anliker M; Weinstock C; Skerra A; Simmet T; Schrezenmeier H; Schmidt CQ
Front Immunol; 2019; 10():1639. PubMed ID: 31379839
[No Abstract] [Full Text] [Related]
28. Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment.
Subías Hidalgo M; Martin Merinero H; López A; Anter J; García SP; Ataúlfo Gonzalez-Fernández F; Forés R; Lopez-Trascasa M; Villegas A; Ojeda E; Rodríguez de Córdoba S
Immunobiology; 2017 Feb; 222(2):363-371. PubMed ID: 27644115
[TBL] [Abstract][Full Text] [Related]
29. [New Complement Therapeutics in Complement-Related Diseases].
Wakamiya N; Ohtani K; Hidaka Y; Inoue N
Brain Nerve; 2019 Jun; 71(6):555-564. PubMed ID: 31171752
[TBL] [Abstract][Full Text] [Related]
30. Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Wong EK; Kavanagh D
Transl Res; 2015 Feb; 165(2):306-20. PubMed ID: 25468487
[TBL] [Abstract][Full Text] [Related]
31. Modeling the activation of the alternative complement pathway and its effects on hemolysis in health and disease.
Caruso A; Vollmer J; Machacek M; Kortvely E
PLoS Comput Biol; 2020 Oct; 16(10):e1008139. PubMed ID: 33006965
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic complement inhibition – from experimental to clinical medicine.
Lappegård KT; Bjerre A; Tjønnfjord GE; Mollnes TE
Tidsskr Nor Laegeforen; 2015 Oct; 135(19):1745-9. PubMed ID: 26486669
[TBL] [Abstract][Full Text] [Related]
33. Ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria.
Lee JW; Kulasekararaj AG
Expert Opin Biol Ther; 2020 Mar; 20(3):227-237. PubMed ID: 32011183
[No Abstract] [Full Text] [Related]
34. C3-mediated extravascular hemolysis in PNH on eculizumab: Mechanism and clinical implications.
Notaro R; Sica M
Semin Hematol; 2018 Jul; 55(3):130-135. PubMed ID: 30032749
[TBL] [Abstract][Full Text] [Related]
35. Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial.
Risitano AM; Röth A; Soret J; Frieri C; de Fontbrune FS; Marano L; Alashkar F; Benajiba L; Marotta S; Rozenberg I; Milojevic J; End P; Nidamarthy PK; Junge G; Peffault de Latour R
Lancet Haematol; 2021 May; 8(5):e344-e354. PubMed ID: 33765419
[TBL] [Abstract][Full Text] [Related]
36. [Novel therapeutics for paroxysmal nocturnal hemoglobinuria].
Nishimura JI
Rinsho Ketsueki; 2021; 62(5):463-471. PubMed ID: 34108330
[TBL] [Abstract][Full Text] [Related]
37. Effective eculizumab therapy followed by BMT in a boy with paroxysmal nocturnal hemoglobinuria.
Oshiro H; Goi K; Akahane K; Inukai T; Sugita K
Pediatr Int; 2015 Apr; 57(2):e27-9. PubMed ID: 25868955
[TBL] [Abstract][Full Text] [Related]
38. COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria.
Gerber GF; Yuan X; Yu J; Cher BAY; Braunstein EM; Chaturvedi S; Brodsky RA
Blood; 2021 Jul; 137(26):3670-3673. PubMed ID: 33945618
[No Abstract] [Full Text] [Related]
39. Post-Allogeneic Hematopoietic Stem Cell Transplantation Eculizumab as Prophylaxis Against Hemolysis and Thrombosis for Patients with Hematologic Disorders Associated with Paroxysmal Nocturnal Hemoglobinuria Clones.
Mei M; Gupta R; O'Donnell M; Al Malki MM; Aldoss I; Ali H; Farol L; Snyder D; Forman SJ; Nakamura R; Khaled S
Biol Blood Marrow Transplant; 2019 May; 25(5):e183-e185. PubMed ID: 30708188
[TBL] [Abstract][Full Text] [Related]
40. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria.
Hillmen P; Elebute M; Kelly R; Urbano-Ispizua A; Hill A; Rother RP; Khursigara G; Fu CL; Omine M; Browne P; Rosse W
Am J Hematol; 2010 Aug; 85(8):553-9. PubMed ID: 20658586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
